Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotype.

Allergy and asthma proceedings - 1 Mar 2025

Kayikci Hazal, Damadoglu Ebru, Cihanbeylerden Melek, Tuccar Cise, Karakaya Gul, Kalyoncu Ali Fuat

Abstract excerpt

Background: The data on subphenotypes and treatment responses to biologicals in late-onset asthma (LOA) is limited. This study aims to compare the clinical characteristics and treatment responses in severe asthma patients receiving biological treatments, categorized into early-onset asthma (EOA) and LOA groups. Methods: Patients treated with omalizumab or mepolizumab for at least six months at a tertiary care...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to Aged
Share to Anti-Asthmatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Asthma

Share to Eosinophils

Share to Forced Expiratory Volume

Share to Treatment Outcome

Source

Identifiers

PMID: 40011985
DOI: 10.2500/aap.2025.46.240105

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotype.PMID 40011985Read ↗

Severe asthma phenotypes in patients controlled with omalizumab: A real-world study.Semantic proximity Read ↗

Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted ApproachSemantic proximity Read ↗

The efficacy of omalizumab treatment in patients with non-atopic severe asthmaSemantic proximity Read ↗

EAACI Biologicals Guidelines-Recommendations for severe asthma.Semantic proximity Read ↗

Current treatment of severe asthma.Semantic proximity Read ↗

Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.Semantic proximity Read ↗

Clinical Recommendations for the Management of Biological Treatments in Severe Asthma Patients: A Consensus Statement.Semantic proximity Read ↗

Adult-onset asthma: is it really different?Semantic proximity Read ↗

Clinical implications of asthma endotypes and phenotypes.Semantic proximity Read ↗

Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient.Semantic proximity Read ↗

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read ↗

Choice of biologics in asthma endotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.